



PATENT

Case Docket No. ELITRA.001A

Date: April 9, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Zyskind, et al.

Appl. No. : 09/492,709

Filed : January 27, 2000

For : GENES IDENTIFIED AS
REQUIRED FOR
PROLIFERATION IN
ESCHERICHIA COLI

Examiner : A. Marschel

Group Art Unit : 1631

) I hereby certify that this correspondence and all
) marked attachments are being deposited with the
) United States Postal Service as first class mail in
) an envelope addressed to: United States Patent
) and Trademark Office, P.O. Box 2327,
) Arlington, VA 22202, on

April 9, 2003

(Date)

Daniel Hart

Daniel Hart, Reg. No. 40,637

TRANSMITTAL LETTER

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) A Supplemental Information Disclosure Statement.
- (X) A PTO Form 1449 with three (3) references.
- (X) A check is enclosed in the amount of \$180 to cover the fees set forth in 37 C.F.R. §1.17(p).
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Daniel Hart

Daniel Hart

Registration No. 40,637

Attorney of Record

Customer No. 20,995


(619) 235-8550

RECEIVED

APR 16 2003

TECH CENTER 1600/2900

ELITRA.001A



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Zyskind, et al.) Group Art Unit 1631
App. No. : 09/492,709)
Filed : January 27, 2000)
For : GENES IDENTIFIED AS REQUIRED)
FOR PROLIFERATION IN)
ESCHERICHIA COLI)
Examiner : A. Marschel)

RECEIVED
APR 16 2003
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing three (3) references that are also enclosed. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(c)(2) before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

04/15/2003 HGUTEMA1 00000037 09492709

01 FC:1806

180.00 OP

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 9, 2003

By: Daniel Hart

Daniel Hart

Registration No. 40,637

Attorney of Record

Customer No. 20,995

(619) 235-8550

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ELITRA.001AAPPLICATION NO.
09/492,709SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Zyskind, et al.FILING DATE
January 27, 2000GROUP
1631

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

RECEIVED
APR 16 2003
TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	1	Bennett, F. C. 1998. Antisense oligonucleotides: Is the glass half full or half empty? <i>Biochemical Pharmacology</i> , 55:9-19.
	2	Crooke, S. T. 1998. An overview of progress in antisense therapeutics. <i>Antisense & Nucleic Acid Drug Development</i> , 8:115-122.
	3	Gura, T. 1995. Antisense has growing pains. <i>Science</i> , 270:575-577.

S:\DOCS\DOH\DOH-7374.DOC:dmb
032503

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.